Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 33 citing articles:

Pharmacotherapy of type 2 diabetes: An update and future directions
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 90
Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study
Han Eol Jeong, Sohee Park, Yunha Noh, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 22
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
Alba Sebastián-Martín, Belén G. Sánchez, José María Mora-Rodríguez, et al.
Biomedicines (2022) Vol. 10, Iss. 8, pp. 2026-2026
Open Access | Times Cited: 31
Type 2 Diabetes Mellitus and COVID-19: A Narrative Review
Cristina Rey‐Reñones, Sara Martínez-Torres, Francisco Martín‐Luján, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2089-2089
Open Access | Times Cited: 30
Diabetic endothelial microangiopathy and pulmonary dysfunction
Lanlan Zhang, Faming Jiang, Yingying Xie, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 16
Antidiabetic agent use and clinical outcomes in patients with diabetes hospitalized for COVID-19: a systematic review and meta-analysis
Jordan N. Keels, Isabella R. McDonald, Christopher S. Lee, et al.
Frontiers in Endocrinology (2025) Vol. 15
Open Access
SGLT2 Inhibitors in COVID-19: Umbrella Review, Meta-Analysis, and Bayesian Sensitivity Assessment
Vinay Suresh, Muhammad Aaqib Shamim, Victor Ghosh, et al.
Diseases (2025) Vol. 13, Iss. 3, pp. 67-67
Open Access
Time to Stop Using Ineffective Covid-19 Drugs
Salim S. Abdool Karim, Nikita Devnarain
New England Journal of Medicine (2022) Vol. 387, Iss. 7, pp. 654-655
Open Access | Times Cited: 26
The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies
Zhi-Hui Song, Qiao-Ming Huang, Shan-Shan Xu, et al.
Therapeutic Innovation & Regulatory Science (2024) Vol. 58, Iss. 4, pp. 773-787
Closed Access | Times Cited: 3
Sequelae of long COVID, known and unknown: A review of updated information
Tetsuya Asakawa, Qingxian Cai, Jiayin Shen, et al.
BioScience Trends (2023) Vol. 17, Iss. 2, pp. 85-116
Open Access | Times Cited: 9
Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19
Carmen Tisch, Eleni Xourgia, Aristomenis K. Exadaktylos, et al.
Endocrine (2024) Vol. 85, Iss. 2, pp. 660-675
Open Access | Times Cited: 2
Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy
Jelena Dimnjaković, Tamara Buble, Pero Ivanko, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Analysis of risk factors for COVID-19-related fatal outcome in 337991 patients with type 1 and type 2 diabetes mellitus in 2020–2022 years: Russian nationwide retrospective study
Н. Г. Мокрышева, М. В. Шестакова, Olga Konstantinovna Vikulova, et al.
Diabetes Mellitus (2022) Vol. 25, Iss. 5, pp. 404-417
Open Access | Times Cited: 13
A study of glycemic perturbations following two doses of COVID-19 vaccination for patients with diabetes: the impacts of vaccine type and anti-diabetes drugs
Cheng-Wei Lin, Shih‐Yuan Hung, I‐Wen Chen
Diabetology & Metabolic Syndrome (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Association of anti-diabetic drugs and covid-19 outcomes in patients with diabetes mellitus type 2 and chronic kidney disease: Nationwide registry analysis
Jelena Dimnjaković, Tamara Buble, Pero Ivanko, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0301056-e0301056
Open Access | Times Cited: 1
Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity
Klara R. Klein, Trine J. Abrahamsen, Anna R. Kahkoska, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1169-1186
Open Access | Times Cited: 1
Impact of the COVID-19 pandemic on antidiabetic drugs initiation in Sweden, an interrupted time series study
Nataliia Khanyk, Fredrik Nyberg, Björn Wettermark, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
The impact of innovative glucose-lowering drugs on the course and outcome of COVID-19 in patients with type 2 diabetes mellitus
Т. Н. Маркова, M. Stas
Diabetes Mellitus (2024) Vol. 27, Iss. 2, pp. 174-184
Open Access | Times Cited: 1
Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program
Steve Johnson, Sajjad Abedian, Til Stürmer‎, et al.
Diabetes Care (2024) Vol. 47, Iss. 11, pp. 1930-1940
Closed Access | Times Cited: 1
Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy
Vincenzo Maria Monda, Claudio Voci, Felice Strollo, et al.
Diabetes Therapy (2023) Vol. 14, Iss. 12, pp. 2127-2142
Open Access | Times Cited: 3
Statistical analysis of small business survival under the shock of multiple COVID-19 waves: A case study from Wuhan, China
Fan Li, Matteo Rubinato, Tao Zhou, et al.
Frontiers in Environmental Science (2023) Vol. 11
Open Access | Times Cited: 2
Antidiabetic Treatment before Hospitalization and Admission Parameters in Patients with Type 2 Diabetes, Obesity, and SARS-CoV-2 Viral Infection
Patricia-Andrada Reștea, Mariana Mureşan, Adrian Voicu, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 3, pp. 392-392
Open Access | Times Cited: 2
Effects of novel glucose-lowering drugs on the COVID-19 patients with diabetes: A network meta-analysis of clinical outcomes
Yang Yang, Ling Zhao, Yeying Wang, et al.
International Journal of Diabetes in Developing Countries (2023) Vol. 44, Iss. 3, pp. 426-436
Open Access | Times Cited: 2
Association of Cardiovascular Disease, Respiratory Diseases, and Diabetes Treatment With COVID-19 Mortality in Hospitalized Patients
Zeinab Nikniaz, Masood Faghih Dinevari, Leila Mokhtari
International Journal of Drug Research in Clinics (2023) Vol. 1, pp. e21-e21
Open Access | Times Cited: 2
SGLT2 Inhibitors in COVID-19: Umbrella Review, Meta-analysis, and Bayesian Sensitivity Assessment
Vinay Suresh, Muhammad Aaqib Shamim, Victor Ghosh, et al.
Research Square (Research Square) (2024)
Open Access
Page 1 - Next Page

Scroll to top